A detailed history of Wasatch Advisors Inc transactions in Exact Sciences Corp stock. As of the latest transaction made, Wasatch Advisors Inc holds 437,873 shares of EXAS stock, worth $25.2 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
437,873
Previous 507,187 13.67%
Holding current value
$25.2 Million
Previous $21.4 Million 39.14%
% of portfolio
0.15%
Previous 0.12%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$42.43 - $70.83 $2.94 Million - $4.91 Million
-69,314 Reduced 13.67%
437,873 $29.8 Million
Q2 2024

Aug 14, 2024

BUY
$41.33 - $74.26 $8.59 Million - $15.4 Million
207,939 Added 69.49%
507,187 $21.4 Million
Q1 2024

Apr 18, 2024

BUY
$56.27 - $73.77 $2.12 Million - $2.78 Million
37,668 Added 14.4%
299,248 $20.7 Million
Q4 2023

Feb 14, 2024

SELL
$59.06 - $75.72 $782,426 - $1 Million
-13,248 Reduced 4.82%
261,580 $19.4 Million
Q3 2023

Nov 14, 2023

SELL
$65.94 - $99.04 $3.23 Million - $4.85 Million
-48,954 Reduced 15.12%
274,828 $18.7 Million
Q2 2023

Aug 07, 2023

SELL
$62.68 - $95.05 $1.68 Million - $2.54 Million
-26,726 Reduced 7.62%
323,782 $30.4 Million
Q1 2023

May 12, 2023

SELL
$47.19 - $70.77 $5.01 Million - $7.51 Million
-106,120 Reduced 23.24%
350,508 $23.8 Million
Q4 2022

Feb 14, 2023

SELL
$30.35 - $53.15 $5.18 Million - $9.08 Million
-170,746 Reduced 27.22%
456,628 $22.6 Million
Q3 2022

Nov 14, 2022

BUY
$31.97 - $49.37 $5.17 Million - $7.98 Million
161,734 Added 34.73%
627,374 $20.4 Million
Q2 2022

Aug 12, 2022

BUY
$35.61 - $76.23 $5.66 Million - $12.1 Million
159,064 Added 51.88%
465,640 $18.3 Million
Q1 2022

May 13, 2022

SELL
$57.56 - $82.54 $267,251 - $383,233
-4,643 Reduced 1.49%
306,576 $21.4 Million
Q4 2021

Feb 15, 2022

SELL
$72.5 - $100.68 $37,265 - $51,749
-514 Reduced 0.16%
311,219 $24.2 Million
Q3 2021

Nov 12, 2021

BUY
$90.24 - $124.05 $215,402 - $296,107
2,387 Added 0.77%
311,733 $29.8 Million
Q2 2021

Aug 12, 2021

BUY
$93.66 - $139.27 $5.57 Million - $8.29 Million
59,508 Added 23.82%
309,346 $38.5 Million
Q1 2021

May 10, 2021

SELL
$116.57 - $155.01 $15.1 Million - $20 Million
-129,146 Reduced 34.08%
249,838 $32.9 Million
Q4 2020

Feb 12, 2021

SELL
$99.61 - $142.12 $31,377 - $44,767
-315 Reduced 0.08%
378,984 $50.2 Million
Q3 2020

Nov 10, 2020

BUY
$72.92 - $102.01 $8.79 Million - $12.3 Million
120,531 Added 46.58%
379,299 $38.7 Million
Q2 2020

Aug 12, 2020

SELL
$55.75 - $92.75 $1.52 Million - $2.53 Million
-27,321 Reduced 9.55%
258,768 $22.5 Million
Q1 2020

May 08, 2020

SELL
$37.9 - $104.44 $16.4 Million - $45.2 Million
-432,605 Reduced 60.19%
286,089 $16.6 Million
Q4 2019

Feb 13, 2020

BUY
$77.66 - $99.74 $222,573 - $285,854
2,866 Added 0.4%
718,694 $66.5 Million
Q3 2019

Nov 14, 2019

SELL
$90.37 - $122.49 $368,257 - $499,146
-4,075 Reduced 0.57%
715,828 $64.7 Million
Q2 2019

Aug 07, 2019

SELL
$89.51 - $118.04 $8.68 Million - $11.4 Million
-96,957 Reduced 11.87%
719,903 $0
Q1 2019

May 08, 2019

SELL
$61.98 - $96.5 $8.55 Million - $13.3 Million
-138,001 Reduced 14.45%
816,860 $0
Q4 2018

Feb 14, 2019

BUY
$56.04 - $82.66 $120,037 - $177,057
2,142 Added 0.22%
954,861 $60.3 Million
Q3 2018

Nov 07, 2018

SELL
$48.29 - $80.6 $7.07 Million - $11.8 Million
-146,347 Reduced 13.32%
952,719 $0
Q2 2018

Aug 02, 2018

SELL
$37.84 - $69.96 $1.91 Million - $3.53 Million
-50,418 Reduced 4.39%
1,099,066 $0
Q1 2018

May 02, 2018

SELL
$39.82 - $57.53 $4.84 Million - $7 Million
-121,659 Reduced 9.57%
1,149,484 $0
Q4 2017

Jan 16, 2018

SELL
$46.49 - $60.51 $13.4 Million - $17.4 Million
-287,868 Reduced 18.46%
1,271,143 $0
Q3 2017

Nov 08, 2017

SELL
$37.05 - $47.12 $15.9 Million - $20.2 Million
-427,908 Reduced 21.54%
1,559,011 $0
Q2 2017

Aug 16, 2017

BUY
N/A
1,986,919
1,986,919 $0

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Wasatch Advisors Inc Portfolio

Follow Wasatch Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wasatch Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wasatch Advisors Inc with notifications on news.